The Epstein-Barr virus candidate vaccine antigen gp340/220 is highly conserved between virus types A and B.

2.50
Hdl Handle:
http://hdl.handle.net/10541/104512
Title:
The Epstein-Barr virus candidate vaccine antigen gp340/220 is highly conserved between virus types A and B.
Authors:
Lees, Janice F; Arrand, Jane E; Pepper, Stuart D; Stewart, James P; Mackett, Mike; Arrand, John R
Abstract:
Anti-Epstein-Barr Virus (EBV) vaccines are being developed which are based on the gp340/220 membrane antigen (MA) gene products from the B95-8 strain. Some proteins are known to be immunologically quite different between type-A (1) and type-B (2) strains of EBV and therefore from a vaccine point of view it was critical to evaluate the degree of conservation of gp340/220. The complete MA coding sequence was determined for two B-type viruses, AG876 and P3HR-1, for comparison with the A-type B95-8. A variable region within MA was sequenced from several other strains. In addition the other open reading frames within the MA-containing BamHI-L fragment of AG876 were sequenced and compared. The results show that there is a high degree of homology between all strains examined. Although some differences were found within the MA coding sequence the only major site of variation was within the repeat region and no consistent A/B changes were found. Monoclonal antibodies generated against A-type MA and representing six epitope groups along the length of the gp340 molecule were found to recognize B-type gp340, thereby demonstrating functional homology. We conclude that, as a vaccine antigen, B95-8 gp340/220 should be equally effective against both types of EBV.
Affiliation:
Cancer Research Campaign Laboratories, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester M20 9BX, United Kingdom.
Citation:
The Epstein-Barr virus candidate vaccine antigen gp340/220 is highly conserved between virus types A and B. 1993, 195 (2):578-86 Virology
Journal:
Virology
Issue Date:
Aug-1993
URI:
http://hdl.handle.net/10541/104512
PubMed ID:
8393237
Type:
Article
Language:
en
ISSN:
0042-6822
Appears in Collections:
All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorLees, Janice Fen
dc.contributor.authorArrand, Jane Een
dc.contributor.authorPepper, Stuart Den
dc.contributor.authorStewart, James Pen
dc.contributor.authorMackett, Mikeen
dc.contributor.authorArrand, John Ren
dc.date.accessioned2010-06-09T16:04:16Z-
dc.date.available2010-06-09T16:04:16Z-
dc.date.issued1993-08-
dc.identifier.citationThe Epstein-Barr virus candidate vaccine antigen gp340/220 is highly conserved between virus types A and B. 1993, 195 (2):578-86 Virologyen
dc.identifier.issn0042-6822-
dc.identifier.pmid8393237-
dc.identifier.urihttp://hdl.handle.net/10541/104512-
dc.description.abstractAnti-Epstein-Barr Virus (EBV) vaccines are being developed which are based on the gp340/220 membrane antigen (MA) gene products from the B95-8 strain. Some proteins are known to be immunologically quite different between type-A (1) and type-B (2) strains of EBV and therefore from a vaccine point of view it was critical to evaluate the degree of conservation of gp340/220. The complete MA coding sequence was determined for two B-type viruses, AG876 and P3HR-1, for comparison with the A-type B95-8. A variable region within MA was sequenced from several other strains. In addition the other open reading frames within the MA-containing BamHI-L fragment of AG876 were sequenced and compared. The results show that there is a high degree of homology between all strains examined. Although some differences were found within the MA coding sequence the only major site of variation was within the repeat region and no consistent A/B changes were found. Monoclonal antibodies generated against A-type MA and representing six epitope groups along the length of the gp340 molecule were found to recognize B-type gp340, thereby demonstrating functional homology. We conclude that, as a vaccine antigen, B95-8 gp340/220 should be equally effective against both types of EBV.en
dc.language.isoenen
dc.subject.meshAmino Acid Sequence-
dc.subject.meshAntibodies, Monoclonal-
dc.subject.meshAntigens, Viral-
dc.subject.meshBase Sequence-
dc.subject.meshCell Line-
dc.subject.meshConserved Sequence-
dc.subject.meshDNA, Viral-
dc.subject.meshFluorescent Antibody Technique-
dc.subject.meshHerpesvirus 4, Human-
dc.subject.meshHumans-
dc.subject.meshMolecular Sequence Data-
dc.subject.meshPolymerase Chain Reaction-
dc.subject.meshSequence Homology, Amino Acid-
dc.subject.meshViral Matrix Proteins-
dc.subject.meshViral Vaccines-
dc.titleThe Epstein-Barr virus candidate vaccine antigen gp340/220 is highly conserved between virus types A and B.en
dc.typeArticleen
dc.contributor.departmentCancer Research Campaign Laboratories, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester M20 9BX, United Kingdom.en
dc.identifier.journalVirologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.